Laudanum synthesizing various opioids, such as propoxyphene, oxymorphone and oxycodone. These synthetic opioids, along with codeine and morphine were preferable to laudanum since a single opioid could be prescribed for different types of pain rather than the "cocktail" of laudanum, which contains nearly all of the opium alkaloids. Consequently, laudanum became mostly obsolete as an analgesic, since its principal ingredient is morphine, which can be prescribed by itself to treat pain. Until now, there has been no medical consensus on which of the two (laudanum or morphine alone) is the better choice for treating pain. In 1970, the US adopted the
Drug Houses of Australia Drug Houses of Australia Drug Houses of Australia (DHA) was originally established in 1936 as an amalgamation of seven Australian pharmaceutical companies, notably A. M. Bickford & Sons. In 1970, DHA was taken over by the British bank Slater Walker. Drug Houses of Australia is now a leading generic pharmaceutics and Chinese proprietary medicine (CPM) manufacturer based in Jurong, Singapore. It was sold to Strides Arcolab through a share purchase agreement with Haw Par Healthcare Limited, Singapore in September 2006 for approximately SGD$19.7 million. It is currently a part of Strides Arcolab which is listed on both the Indian stock